Exact Mass: 255.0062992
Exact Mass Matches: 255.0062992
Found 48 metabolites which its exact mass value is equals to given mass value 255.0062992,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Sulfathiazole
C9H9N3O2S2 (255.01361740000002)
Sulfathiazole is only found in individuals that have used or taken this drug.It is a short-acting sulfa drug. It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide. CONFIDENCE standard compound; INTERNAL_ID 1024; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2323; ORIGINAL_PRECURSOR_SCAN_NO 2321 CONFIDENCE standard compound; INTERNAL_ID 1024; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2327; ORIGINAL_PRECURSOR_SCAN_NO 2325 CONFIDENCE standard compound; INTERNAL_ID 1024; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7417; ORIGINAL_PRECURSOR_SCAN_NO 7415 CONFIDENCE standard compound; INTERNAL_ID 1024; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2326; ORIGINAL_PRECURSOR_SCAN_NO 2324 CONFIDENCE standard compound; INTERNAL_ID 1024; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2315; ORIGINAL_PRECURSOR_SCAN_NO 2312 CONFIDENCE standard compound; INTERNAL_ID 1024; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7355; ORIGINAL_PRECURSOR_SCAN_NO 7354 CONFIDENCE standard compound; INTERNAL_ID 1024; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7401; ORIGINAL_PRECURSOR_SCAN_NO 7397 CONFIDENCE standard compound; INTERNAL_ID 1024; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7346; ORIGINAL_PRECURSOR_SCAN_NO 7344 CONFIDENCE standard compound; INTERNAL_ID 1024; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2323; ORIGINAL_PRECURSOR_SCAN_NO 2320 CONFIDENCE standard compound; INTERNAL_ID 1024; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2314; ORIGINAL_PRECURSOR_SCAN_NO 2312 CONFIDENCE standard compound; INTERNAL_ID 1024; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7406; ORIGINAL_PRECURSOR_SCAN_NO 7404 CONFIDENCE standard compound; INTERNAL_ID 1024; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7390; ORIGINAL_PRECURSOR_SCAN_NO 7388 D - Dermatologicals > D06 - Antibiotics and chemotherapeutics for dermatological use > D06B - Chemotherapeutics for topical use > D06BA - Sulfonamides J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01E - Sulfonamides and trimethoprim > J01EB - Short-acting sulfonamides C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent D000890 - Anti-Infective Agents > D013432 - Sulfathiazoles D000890 - Anti-Infective Agents > D013424 - Sulfanilamides CONFIDENCE standard compound; EAWAG_UCHEM_ID 185 CONFIDENCE standard compound; INTERNAL_ID 2360 CONFIDENCE standard compound; INTERNAL_ID 1023 KEIO_ID S079; [MS2] KO009251 KEIO_ID S079
Phosfolan
ORIGINAL_ACQUISITION_NO 7370; CONFIDENCE standard compound; INTERNAL_ID 1078; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_PRECURSOR_SCAN_NO 7368 CONFIDENCE standard compound; INTERNAL_ID 1078; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7337; ORIGINAL_PRECURSOR_SCAN_NO 7335 CONFIDENCE standard compound; INTERNAL_ID 1078; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7325; ORIGINAL_PRECURSOR_SCAN_NO 7323 CONFIDENCE standard compound; INTERNAL_ID 1078; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7376; ORIGINAL_PRECURSOR_SCAN_NO 7374 CONFIDENCE standard compound; INTERNAL_ID 1078; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7406; ORIGINAL_PRECURSOR_SCAN_NO 7404 CONFIDENCE standard compound; INTERNAL_ID 1078; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7355; ORIGINAL_PRECURSOR_SCAN_NO 7354 CONFIDENCE standard compound; INTERNAL_ID 1078; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7370; ORIGINAL_PRECURSOR_SCAN_NO 7368
lamotrigine
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002491 - Central Nervous System Agents > D000927 - Anticonvulsants D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators CONFIDENCE standard compound; INTERNAL_ID 1528 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 86 CONFIDENCE standard compound; EAWAG_UCHEM_ID 2676
Lamotrigine
Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder. For epilepsy it is used to treat partial seizures, primary and secondary tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. Lamotrigine also acts as a mood stabilizer. It is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. Chemically unrelated to other anticonvulsants, lamotrigine has relatively few side-effects and does not require blood monitoring. The exact way lamotrigine works is unknown. [Wikipedia] D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002491 - Central Nervous System Agents > D000927 - Anticonvulsants D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators
Anagrelide
C10H7Cl2N3O (254.99661519999998)
Anagrelide is only found in individuals that have used or taken this drug. It is a drug used for the treatment of essential thrombocytosis (ET; essential thrombocythemia). It also has been used in the treatment of chronic myeloid leukemia. [Wikipedia]The mechanism by which anagrelide reduces blood platelet count is still under investigation. Studies in patients support a hypothesis of dose-related reduction in platelet production resulting from a decrease in megakaryocyte hypermaturation. In blood withdrawn from normal volunteers treated with anagrelide, a disruption was found in the postmitotic phase of megakaryocyte development and a reduction in megakaryocyte size and ploidy. At therapeutic doses, anagrelide does not produce significant changes in white cell counts or coagulation parameters, and may have a small, but clinically insignificant effect on red cell parameters. Anagrelide inhibits cyclic AMP phosphodiesterase III (PDEIII). PDEIII inhibitors can also inhibit platelet aggregation. However, significant inhibition of platelet aggregation is observed only at doses of anagrelide higher than those required to reduce platelet count. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents D050299 - Fibrin Modulating Agents D002317 - Cardiovascular Agents
Irsogladine
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent D020011 - Protective Agents > D011837 - Radiation-Protective Agents D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D020011 - Protective Agents > D016588 - Anticarcinogenic Agents D000970 - Antineoplastic Agents Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder. Target: PDE4; mACHR Irsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3\% (P < 0.02, P < 0.001), in tPA-deficient mice by 42.6 and 46\% (P < 0.001, P < 0.001), and in uPA-deficient mice by 27.2 and 46\% (P < 0.05, p < 0.001), respectively. Irsogladine inhibits bFGF-induced angiogenesis in wild-type, tPA-knockout, and uPA-knockout mice [1]. Irsogladine up-regulates GJIC between PC cells via regulation of the PKA pathway. It also suggests a useful adjuvant of Irsogladine to pancreatic cancer therapy [2]. irsogladine produces the increase of intracellular cAMP content via non-selective inhibition of PDE isozymes, which may be a key mechanism involved in its gastroprotective actions [3].
Irsogladine
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent D020011 - Protective Agents > D011837 - Radiation-Protective Agents D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D020011 - Protective Agents > D016588 - Anticarcinogenic Agents D000970 - Antineoplastic Agents Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder. Target: PDE4; mACHR Irsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3\% (P < 0.02, P < 0.001), in tPA-deficient mice by 42.6 and 46\% (P < 0.001, P < 0.001), and in uPA-deficient mice by 27.2 and 46\% (P < 0.05, p < 0.001), respectively. Irsogladine inhibits bFGF-induced angiogenesis in wild-type, tPA-knockout, and uPA-knockout mice [1]. Irsogladine up-regulates GJIC between PC cells via regulation of the PKA pathway. It also suggests a useful adjuvant of Irsogladine to pancreatic cancer therapy [2]. irsogladine produces the increase of intracellular cAMP content via non-selective inhibition of PDE isozymes, which may be a key mechanism involved in its gastroprotective actions [3].
1-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-yl)ethanone
C10H7Cl2N3O (254.99661519999998)
sulfathiazole
C9H9N3O2S2 (255.01361740000002)
D - Dermatologicals > D06 - Antibiotics and chemotherapeutics for dermatological use > D06B - Chemotherapeutics for topical use > D06BA - Sulfonamides J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01E - Sulfonamides and trimethoprim > J01EB - Short-acting sulfonamides C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent D000890 - Anti-Infective Agents > D013432 - Sulfathiazoles D000890 - Anti-Infective Agents > D013424 - Sulfanilamides
PRP_M256
C10H7Cl2N3O (254.99661519999998)
CONFIDENCE Transformation product, tentative ID (Level 2b); INTERNAL_ID 2404
anagrelide
C10H7Cl2N3O (254.99661519999998)
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents D050299 - Fibrin Modulating Agents D002317 - Cardiovascular Agents
2,4-dichloro-6-(4-methoxyphenyl)-1,3,5-triazine
C10H7Cl2N3O (254.99661519999998)
Creatine phosphate disodium salt
Phosphocreatine disodium, one of organic compounds known as alpha amino acids and derivatives, is a substrate for the determination of creatine kinase and used to regenerate ATP during skeletal muscle contraction[1]. Phosphocreatine disodium, one of organic compounds known as alpha amino acids and derivatives, is a substrate for the determination of creatine kinase and used to regenerate ATP during skeletal muscle contraction[1].
3-[Cyano(2,4-Dichlorophenyl)Methylene]Carbazamidine
5-pyridin-2-ylthiophene-2-sulfonohydrazide
C9H9N3O2S2 (255.01361740000002)
Methyl 6-chloro-3-(Methylthio)-1H-indole-5-carboxylate
1-(5-Bromopyrimidin-2-yl)-4-piperidinone
C9H10BrN3O (255.00071899999998)
2,6-DICHLORO-4-[(DIMETHYLAMINO)METHYL]PHENOL HYDROCHLORIDE
ETHYL 3-AMINO-4-CHLOROBENZO[B!THIOPHEN-2-CARBOXYLATE
3,4-Dichloro-5-fluoro-[1,1-biphenyl]-2-amine
C12H8Cl2FN (255.00177999999997)
4-Thiazoleacetic acid, 2-phenyl-, hydrochloride (1:1)
2-chloromethyl-3,4-dimethoxy pyridine hydrochloride
C9H9N3O2S2 (255.01361740000002)
3-Bromo-1-oxa-8-azaspiro[4.5]decane hydrochloride (1:1)
thiazosulfone
C9H9N3O2S2 (255.01361740000002)
C254 - Anti-Infective Agent > C849 - Sulfone Anti-Infective Agent
2-AMINO-3-(5-CHLOROBENZOóB!THIOPHEN-3-YL)PROPANOIC ACID, TECH
(2Z)-2-[Cyano(2,3-dichlorophenyl)methylene]hydrazinecarboximidamide
2-(2,3-Dichlorophenyl)-2-guanidinyliminoacetonitrile
Methyl 7-chloro-8-fluoro-4-hydroxyquinoline-2-carboxylate
Disodium (1-methyl-4-oxoimidazolidin-2-ylidene)phosphoramidate
4-(2-MORPHOLIN-4-YL-ETHOXY)-BENZOIC ACID
C9H10BrN3O (255.00071899999998)
sodium,2-chloro-4-[(4-oxocyclohexa-2,5-dien-1-ylidene)amino]phenolate
3-(2-Chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxylic acid
Sparfosic acid
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite D018377 - Neurotransmitter Agents > D018846 - Excitatory Amino Acids D000890 - Anti-Infective Agents > D000998 - Antiviral Agents D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors C471 - Enzyme Inhibitor
N-(Phosphonoacetyl)aspartic acid
D018377 - Neurotransmitter Agents > D018846 - Excitatory Amino Acids D000890 - Anti-Infective Agents > D000998 - Antiviral Agents D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors
2-methoxy-N-(5-thiophen-2-yl-1,3,4-thiadiazol-2-yl)acetamide
C9H9N3O2S2 (255.01361740000002)
4-methylumbelliferone sulfate(1-)
An organosulfate oxoanion that is the conjugate base of 4-methylumbelliferone sulfate, obtained by deprotonation of the sulfo group; major species at pH 7.3.